Shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Analysts have set a 12-month consensus target price of $5.50 for the company and are anticipating that the company will post ($0.14) earnings per share for the current quarter, according to Zacks. Zacks has also assigned AEterna Zentaris an industry rank of 62 out of 256 based on the ratings given to related companies.
Several research analysts have issued reports on the stock. TheStreet raised shares of SUMMIT THERAPEU/S from a “d” rating to a “c-” rating in a research report on Thursday, June 13th. ValuEngine raised shares of China Southern Airlines from a “sell” rating to a “hold” rating in a research report on Tuesday, June 11th. Finally, Zacks Investment Research downgraded shares of KKR & Co Inc from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd.
AEterna Zentaris stock traded up $0.21 during midday trading on Friday, hitting $2.83. 45,303 shares of the company’s stock were exchanged, compared to its average volume of 113,618. AEterna Zentaris has a 12-month low of $1.29 and a 12-month high of $5.57. The stock has a market cap of $44.31 million, a PE ratio of 11.32 and a beta of 1.25. The business has a 50 day moving average price of $2.81.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.04 by ($0.18). AEterna Zentaris had a negative return on equity of 328.95% and a negative net margin of 666.76%. The business had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $4.20 million. Equities analysts forecast that AEterna Zentaris will post 1.71 EPS for the current year.
Institutional investors have recently modified their holdings of the business. Jane Street Group LLC purchased a new stake in shares of AEterna Zentaris in the fourth quarter valued at about $30,000. O Shaughnessy Asset Management LLC purchased a new stake in shares of AEterna Zentaris in the fourth quarter valued at about $66,000. Acadian Asset Management LLC boosted its holdings in shares of AEterna Zentaris by 27.2% in the fourth quarter. Acadian Asset Management LLC now owns 45,049 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 9,640 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of AEterna Zentaris in the first quarter valued at about $179,000. Finally, AJO LP purchased a new stake in shares of AEterna Zentaris in the first quarter valued at about $1,031,000. 13.67% of the stock is currently owned by institutional investors.
AEterna Zentaris Company Profile
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.
Featured Story: What is a short straddle?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.